Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an efavirenz-based regimen

Simple item page
dc.contributor.authorLartey, M.
dc.contributor.authorSagoe, K.W.
dc.contributor.authorYang, H.
dc.contributor.authorKenu, E.
dc.contributor.authorXexemeku, F.
dc.contributor.authorOliver-Commey, J.
dc.contributor.authorBoima, V.
dc.contributor.authorSeshie, M.
dc.contributor.authorSagoe, A.
dc.contributor.authorMingle, J.A.A.
dc.contributor.authorFlanigan, T.P.
dc.contributor.authorWu, H.
dc.contributor.authorKwara, A.
dc.date.accessioned2019-05-03T11:12:04Z
dc.date.available2019-05-03T11:12:04Z
dc.date.issued2011-02
dc.description.abstractViral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P >.05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment. © The Author 2011.en_US
dc.identifier.otherDOI: 10.1093/cid/ciq196
dc.identifier.otherVol.52(4): pp 547-50
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/29765
dc.language.isoenen_US
dc.publisherClinical Infectious Diseasesen_US
dc.titleViral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an efavirenz-based regimenen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Biostatistics